ECCO 2017 | SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations

Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, introduces the SECOMBIT Phase II trial (NCT02631447) in metastatic melanoma with BRAF mutations at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This trial with around 300 patients will address the important question of which sequence of immunotherapy and targeted therapy is most effective. Prof. Ascierto describes the three-armed SECOMBIT trial, which will compare overall survival (OS) in patients receiving immunotherapy (ipilimumab with nivolumab) followed by targeted therapy (encorafenib with binimetinib), targeted therapy followed by immunotherapy, or the sandwich approach where immunotherapy is given between two periods of targeted therapy.